- Home
- PDEX vs IPHA Comparison
PDEX vs IPHA Comparison
Compare PDEX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- IPHA
- Stock Information
- Founded
- PDEX 1978
- IPHA 1999
- Country
- PDEX United States
- IPHA France
- Employees
- PDEX N/A
- IPHA N/A
- Industry
- PDEX Medical/Dental Instruments
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- PDEX Health Care
- IPHA Health Care
- Exchange
- PDEX Nasdaq
- IPHA Nasdaq
- Market Cap
- PDEX 167.6M
- IPHA 160.1M
- IPO Year
- PDEX N/A
- IPHA 2019
- Fundamental
- Price
- PDEX $44.06
- IPHA $1.77
- Analyst Decision
- PDEX Strong Buy
- IPHA Strong Buy
- Analyst Count
- PDEX 1
- IPHA 1
- Target Price
- PDEX $56.00
- IPHA $11.00
- AVG Volume (30 Days)
- PDEX 74.7K
- IPHA 10.6K
- Earning Date
- PDEX 09-04-2025
- IPHA 09-11-2025
- Dividend Yield
- PDEX N/A
- IPHA N/A
- EPS Growth
- PDEX 379.10
- IPHA N/A
- EPS
- PDEX 2.76
- IPHA N/A
- Revenue
- PDEX $64,123,999.00
- IPHA $20,831,349.00
- Revenue This Year
- PDEX $26.92
- IPHA $209.83
- Revenue Next Year
- PDEX $4.48
- IPHA $83.15
- P/E Ratio
- PDEX $15.96
- IPHA N/A
- Revenue Growth
- PDEX 29.65
- IPHA N/A
- 52 Week Low
- PDEX $17.60
- IPHA $1.29
- 52 Week High
- PDEX $70.26
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- PDEX 54.43
- IPHA 42.46
- Support Level
- PDEX $43.59
- IPHA $1.71
- Resistance Level
- PDEX $49.09
- IPHA $1.90
- Average True Range (ATR)
- PDEX 2.29
- IPHA 0.07
- MACD
- PDEX 0.35
- IPHA 0.00
- Stochastic Oscillator
- PDEX 65.81
- IPHA 31.82
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.